Day: September 16, 2025

A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) — The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of collaboration and dedicated support for early-career sleep researchers and future sleep physicians. In 2021, Avadel became the Young Investigator Research Forum’s (YIRF) inaugural corporate sponsor. Thanks to support from Avadel and other companies, YIRF has empowered dozens of trainees and junior faculty in sleep and circadian science, providing them with mentorship, grant-writing training, and networking opportunities that have become a vital steppingstone for launching successful research careers. This past June, Avadel was the lead sponsor of the AASM Fellow Boot Camp which...

Rebrand aligns corporate identity with expanding opportunities in autonomy, defense and intelligence, reinforcing commitment to long-term shareholder value creation WICHITA, Kan., Sept. 16, 2025 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (dba, EagleNXT) (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, provides a shareholder update following its recently announced corporate name change, offering additional detail on the Company’s long-term strategy, market positioning, and brand alignment. EagleNXT CEO Bill Irby commented, “The decision to transition from AgEagle to EagleNXT reflects a clear alignment of our identity with the markets we are targeting and the long-term opportunities ahead. While honoring our agricultural roots, the new name embraces our forward-looking commitment to innovation...

CALGARY, Alberta, Sept. 16, 2025 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“DIRTT”, the “Company”, “we”, “our”, “us” or “ours”) (TSX: DRT; OTC: DRTTF), a leader in industrialized construction, today announced recent project awards and a strengthened forward pipeline, underscoring continued commercial momentum across multiple sectors. DIRTT secured a $3.5 million contract with Google at its Caribbean campus in Sunnyvale, California. The one-million square-foot development spans two buildings and features DIRTT’s latest commercial office innovation, a self-contained pod solution. DIRTT’s 10-year relationship with Google has resulted in more than 250 projects, including its recent New York City headquarters. In healthcare, DIRTT expanded its long-standing relationship with Allina Health for a new flagship project. The...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) — via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of a new Frequently Asked Questions (“FAQ”) page on its corporate website. The new FAQ resource, available at www.izocorp.com/faq, is designed to improve transparency and provide quick access to essential information on the Company’s flagship device, the IzoView Breast CT Imaging System, the Company’s development milestones, and its competitive positioning in the global breast imaging market. The page serves as a strategic informational and investor...

VALENCIA, Spain, Sept. 16, 2025 (GLOBE NEWSWIRE) — Turbo Energy S.A. (Nasdaq: TURB) (“Turbo Energy” or the “Company”), a global provider of leading-edge, AI-optimized solar energy storage technologies and solutions, today announced that it has been selected to supply and implement energy storage projects in Spain with a total capacity of 366 MWh. The projects, valued at approximately $53 million, are scheduled to be executed over the next two years. This large-scale initiative will be developed for a major industrial group in the construction industry. Turbo Energy will provide turnkey integration of the systems, along with its AI-driven energy management platform, for deployment across more than ten industrial facilities with varying technical requirements. These systems will help the factories optimize electricity consumption,...

– Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management – GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of clinical and preclinical data supporting the clinical utility of a biologic envelope that secures cardiac implantable electronic devices (CIEDs), promotes tissue remodeling, and addresses bacterial colonization through localized antibiotic delivery. The data are published in the current issue of Frontiers in Cardiovascular Medicine. The publication includes data from the HEAL study (NCT04645173), a multicenter observational clinical evaluation of patients undergoing CIED reoperations....

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025 Second Fast Track designation granted by FDA for CRB-701NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy. A Fast Track designation for relapsed or refractory metastatic cervical cancer was granted by the FDA in December 2024. CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific,...

MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) — International Money Express, Inc. (NASDAQ: IMXI) (“Intermex” or the “Company”), a leading money remittance provider to Latin America and the Caribbean, today announced the expansion of its Payroll Card Program in partnership with Central Payments. The program enables U.S. employers to digitize payroll disbursement at no additional cost to employers, eliminating the burden of issuing paper checks or handling cash. Employees gain fast, secure access to their wages and the digital economy. “Employers carry a huge operational burden when running payroll with cash and checks. At Intermex, we can eliminate this in just days by digitizing the disbursement process at no cost for employers or employees,” said Marcelo Theodoro, Chief Digital, Product and Marketing Officer for Intermex. “Employees...

FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use Disorder GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced receipt of the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held on July 29, 2025. The minutes provide the FDA’s formal input into the AD04 Phase 3 adaptive clinical trial design and broader clinical development strategy. This positive feedback marks a key milestone in advancing AD04 toward registration. The objective for the EOP2...

In Australia and Europe MADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it continues to expand its patent portfolio for iadademstat and vafidemstat, Oryzon’s clinical-stage LSD1 inhibitors for oncology and central nervous system (CNS) disorders, following new Decisions to Grant from the Australian and European patent offices. The Australian Patent Office has issued a Decision to Grant for Oryzon’s patent application AU2020249493, titled “Combinations of iadademstat for cancer therapy”. The allowed claims cover combinations of iadademstat with PD1 or PD-L1 inhibitors for the treatment of cancer, including small cell lung cancer (SCLC). A Decision to Grant is an...